Results 161 to 170 of about 43,902 (289)

Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)

Безопасность и риск фармакотерапии
INTRODUCTION. Osteoporosis is a leading cause of morbidity, disability, reduced quality of life, and premature mortality in the elderly population. Denosumab is a treatment for osteoporosis; however, denosumab discontinuation may cause a rebound effect ...
N. Yu. Velts, O. V. Velts, R. N. Alyautdin   +2 more
doaj   +1 more source

Pediatric Scoliosis in Osteogenesis Imperfecta: From Genetic Mechanisms to Therapeutic Strategies

Orthopaedic Surgery, Volume 17, Issue 11, Page 3036-3047, November 2025.
This review explores the genetic underpinnings and treatment strategies for spinal deformities in children with osteogenesis imperfecta. Emphasis is placed on emerging molecular insights and modern surgical techniques that improve the management of severe scoliosis and enhance patient outcomes.
Vladislav Muldiiarov, Keely Buesing, Maegen J. Wallace   +2 more
wiley   +1 more source

Melorheostosis: Clinical, radiological, and histopathological features with a literature review

Physiological Reports, Volume 13, Issue 21, November 2025.
Abstract Melorheostosis is a rare sclerosing bone dysplasia that can clinically and radiologically mimic common bone disorders, particularly in atypical presentations. Its heterogeneous manifestations and limited awareness among clinicians frequently contribute to diagnostic delays or misdiagnosis. We report the case of a 34‐year‐old woman with chronic
Elif Koca, Şeyhmus Kavak, Bilal Demir, Nil Comunoglu, Fatih Kantarci, Oguzhan Koca   +5 more
wiley   +1 more source

Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study [PDF]

, 2019
Sahar Nasser, Arwa Sahal, Anas Hamad, Shereen Elazzazy   +3 more
openalex   +1 more source

Review of: "Simplifying the dental/periodontal management of patients with metabolic bone fragility receiving treatment with denosumab" [PDF]

, 2021
Francesco Erovigni
openalex   +1 more source

Denosumab Treatment of Severe Disuse Osteoporosis in a Boy With Spinal Muscular Atrophy

Acta Medica Iranica, 2017
Denosumab is a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand. Denosumab is used in the treatment of postmenopausal osteoporosis and cancer-related bone disorders.
Stepan Kutilek
doaj  

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension [PDF]

, 2013
Henry G. Bone, Roland Chapurlat, Maria Luisa Brandi, Jacques P. Brown, E. J. Czerwiński, Marc-Antoine Krieg, Dan Mellström, S. Radominski, Jean‐Yves Reginster, Heinrich Resch, José Andrés Román Ivorra, C. Roux, Eric Vittinghoff, Nadia Daizadeh, Andrea Wang, Michelle N. Bradley, Nathalie Franchimont, Michelle Geller, Rachel B. Wagman, Steven R. Cummings, Socrates E. Papapoulos   +20 more
openalex   +1 more source

The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong [PDF]

, 2013
published_or_final_versio
Cheung, SKW, Cheung, TC, Choi, PTF, Chow, SLE, Ho, HYA, Ip, TP, Kan, SYA, Kung, WCA, Lee, KK, Leung, KLF, Leung, YYJ, Lo, STS, Sy, CT, Wong, YW   +13 more
core  

Teriparatide and denosumab treatment for pregnancy and lactation-associated osteoporosis with multiple vertebral fractures: A case study

, 2017
Akifumi Ijuin, Hiromi Yoshikata, Ryoko Asano, Taku Tsuburai, Ritsuko Kikuchi, Hideya Sakakibara   +5 more
openalex   +1 more source

AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012 [PDF]

, 2011
Harbeck, Nadia, Scharl, Anton, Thomssen, Christoph   +2 more
core   +2 more sources